You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GD2-positive solid tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)

Recruiting
  • Neuroblastoma
  • +5 more
  • GD2-CART01
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

Solid Tumor Trial in Shenzhen (bi-4SCAR GD2/PSMA T cells)

Recruiting
  • Solid Tumor
  • bi-4SCAR GD2/PSMA T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Neuroblastoma Trial in New York (3F8 Monoclonal Antibody Combined with Interleukin-2)

Completed
  • Neuroblastoma
  • 3F8 Monoclonal Antibody Combined with Interleukin-2
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 26, 2021

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

HER2-positive Advanced Solid Tumors Trial in Shanghai (DP303c)

Recruiting
  • HER2-positive Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 10, 2023

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

SCLC, Malignant Melanoma, Sarcoma Trial (GD2-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • SCLC
  • +2 more
  • GD2-SADA:177Lu-DOTA Complex
  • (no location specified)
May 4, 2022

Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

Not yet recruiting
  • HER2 Positive Advanced Solid Tumors
  • HypoSti.CAR-HER2 T cells
  • +2 more
  • (no location specified)
Jan 12, 2023

Advanced Solid Tumor Trial in Shanghai (IMC008)

Recruiting
  • Advanced Solid Tumor
  • Shanghai, Shanghai, China
    Shanghai Changhai Hospital
Apr 19, 2023

Solid Tumor, KRAS Mutation-Related Tumors Trial in Washington (NEROFE, Doxorubicin)

Recruiting
  • Solid Tumor
  • KRAS Mutation-Related Tumors
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023

Solid Tumor Trial in Beijing (QLS31905, Nab paclitaxel, Gemcitabine)

Not yet recruiting
  • Solid Tumor
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 10, 2023

Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)

Not yet recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • Anti-mesothelin CAR-T cells
  • (no location specified)
Mar 13, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Advanced Solid Tumors Trial in Chongqing (TC-N201 cells, IL-2, Fludarabine)

Recruiting
  • Advanced Solid Tumors
  • TC-N201 cells
  • +4 more
  • Chongqing, China
    TCRCure Biopharma Ltd.
May 25, 2023

Solid Tumors Trial (TCR-T cells, Fludarabine, Cyclophosphamide Capsules)

Not yet recruiting
  • Solid Tumors
  • TCR-T cells
  • +4 more
  • (no location specified)
Dec 12, 2022

Solid Tumor Trial in Wuhan (HPV-T, Interleukin-2)

Recruiting
  • Solid Tumor
  • Wuhan, Hubei, China
    Wuhan Union Hospital
May 31, 2023

Solid Tumor Trial (HER2-E-CART cells)

Not yet recruiting
  • Solid Tumor
  • HER2-E-CART cells
  • (no location specified)
Feb 16, 2023

Metastatic Solid Tumor Trial (TAC01-CLDN18.2)

Not yet recruiting
  • Metastatic Solid Tumor
  • TAC01-CLDN18.2
  • (no location specified)
May 8, 2023

Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

Not yet recruiting
  • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
  • Non-investigational
  • (no location specified)
May 11, 2023

Mesothelin-positive Advanced Malignant Solid Tumors Trial in Hangzhou (UCLM802 Cell Injection (Anti-mesothelin CAR-T cells))

Recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital Zhejiang University School of Medi
May 11, 2023

Advanced Solid Tumor Trial in Beijing (aPD1-MSLN-CAR T Cells)

Not yet recruiting
  • Advanced Solid Tumor
  • αPD1-MSLN-CAR T Cells
  • Beijing, China
    National Cancer Center Cancer Hospital Chinese Academy of Medica
Jul 13, 2023

Gastric Cancer Trial in Qingdao (Chimeric antigen receptor T cell preparation targeting Claudin18.2)

Recruiting
  • Gastric Cancer
  • Chimeric antigen receptor T cell preparation targeting Claudin18.2
  • Qingdao, Shandong, China
    The Affiliated Hospital of Qingdao University
Jul 11, 2023

Solid Tumors, Adult Trial in Dallas, Hangzhou (HF158K1 /Arm 2 mg/m², HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m²)

Not yet recruiting
  • Solid Tumors, Adult
  • HF158K1 /Arm 2 mg/m²
  • +5 more
  • Dallas, Texas
  • +2 more
May 6, 2023